[ad_1]
KITOV PHARMA LT / S (NASDAQ: KTOV) and Enanta Pharmaceuticals (NASDAQ: ENTA) are both medical companies, but what is the top business? We will compare the two companies based on the strength of their valuation, badyst recommendations, risk, profitability, earnings, institutional ownership and dividends.
Analyst Notes
This is a summary of the current ratings and price targets for KITOV PHARMA LT / S and Enanta Pharmaceuticals, provided by MarketBeat.
| Rating of the rating | Clbadification of Notations | Buy Evaluations | Notes Strong | Clbadification | |
| KITOV PHARMA LT / S | 0 | 0 | 1 | 0 | 3.00 |
| Enanta Pharmaceuticals | 0 | 3 | 3 | 0 | 2.50 |
KITOV PHARMA LT / S currently has a consensus target price of 12 , $ 50, suggesting a potential upside of 418.67%. Enanta Pharmaceuticals has a consensus target price of $ 79.17, suggesting a downside potential of 36.82%. Given KITOV PHARMA LT / S's highest consensual rating and its higher upside potential, equity badysts clearly believe that KITOV PHARMA LT / S is more favorable than Enanta Pharmaceuticals.
Insider & Institutional Ownership
0.2% of KITOV PHARMA LT / S shares held by institutional investors. Comparatively, 76.2% of Enanta Pharmaceuticals shares are held by institutional investors. 3.0% of KITOV PHARMA LT / S shares are held by insiders. Comparatively, 10.6% of the shares of Enanta Pharmaceuticals are owned by insiders. Strong institutional ownership indicates that hedge funds, large fund managers and endowments believe that one stock will outperform the market over the long term.
Risk & Volatility
KITOV PHARMA LT / S displays a beta of 2.88 The price of the stock is 188% more volatile than the S & P 500. Comparatively, Enanta Pharmaceuticals has a beta of 1 , 01, indicating that its share price is 1% more volatile than the S & P 500.
Earnings and valuation
Revenue, earnings per share and valuation of PHARMA LT / S and Enanta Pharmaceuticals
| Gross Income | Price / Sales Ratio | Net Income | Earnings Per Equity | Price / Earnings Ratio [19659009] KITOV PHARMA LT / S | N / A | ] N / A | – $ 12.27 million | ($ 1.30) | -1.85 | |
| Enanta Pharmaceuticals | $ 102.81 million | 23.49 | ] $ 17.71 million | $ 0.91 | 137.69 |
Enanta Pharmaceuticals have higher revenues and profits than KITOV PHARMA LT / S. KITOV PHARMA LT / S trades at a r atio price / earnings lower than that of Enanta Pharmaceuticals, indicating that it is currently the most affordable of the two actions.
Profitability
This table compares net margins, return on equity and return on badets of KITOV PHARMA LT / S and Enanta Pharmaceuticals
| Net Margins | Return on Equity [19659005] Return on Assets | ||
| KITOV PHARMA LT / S | N / A | N / A | N / A |
| Enanta Pharmaceuticals | 31.60% | 18.50% | 17.30% |
Synopsis
Enanta Pharmaceuticals defeats KITOV PHARMA LT / S on 10 out of 13 factors compared between the two stocks
About KITOV PHARMA LT / S
About d & # 39; Enanta Pharmaceuticals [19659023] [19459027EnantaPharmaceuticalslogo"title="LogoEnantaPharmaceuticals"clbad="companylogo"/>EnantaPharmaceuticalsIncunesociétédebiotechnologieseconcentresurladécouverteetledéveloppementdemédicamentsàpetitesmoléculespourletraitementdesinfectionsviralesetdesmaladiesdufoieetledéveloppementseconcentresurlesciblesdelamaladie:virusdel'hépatiteBstéatohépatitenonalcooliquecholangitebiliaireprimitiveetvirusrespiratoiresyncytialIlaconcluunaccorddedéveloppementetdelicenceavecAbbottLaboratoriespouridentifierdévelopperetcommercialiserlaprotéaseNS3etNS3/4AduVHCcomposésinhibiteursycomprisleparitapreviretleglecaprevirpourletraitementduvirusdel'hépatiteCchronique
Receive the evaluation of new of KITOV PHARMA LT / S Daily – Enter your email address below to receive a concise summary of the latest news and badyst estimates for KITOV PHARMA LT / S and related companies with the free daily newsletter from MarketBeat.com.
Source link
